SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • April 18th, 2019 • Mateon Therapeutics Inc • Pharmaceutical preparations • Nevada
THIS SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of April , 2019, is entered into by and between MATEON THERAPEUTICS, INC., a Delaware corporation (the “Company”) and PEAK ONE OPPORTUNITY FUND, L.P., a Delaware limited partnership (the “Buyer”).
SEPARATION AGREEMENT AND RELEASESeparation Agreement and Release • April 18th, 2019 • Mateon Therapeutics Inc • Pharmaceutical preparations
THIS SEPARATION AGREEMENT AND RELEASE (“Agreement”) is made and entered into by and between Dr. William D. Schwieterman (“Employee”) and Mateon Therapeutics, Inc. (“Company”), and inures to the benefit of each of Company’s current, former and future, as applicable, subsidiaries, affiliates, related entities, successors, officers, directors, shareholders, agents, employees and assigns. The term “Parties” as used in this Agreement means Company and Employee collectively.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • April 18th, 2019 • Mateon Therapeutics Inc • Pharmaceutical preparations • Nevada
THIS SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of April , 2019, is entered into by and between MATEON THERAPEUTICS, INC., a Delaware corporation (the “Company”) and the individuals identified on the signature page hereto (each a “Buyer” and collectively, the “Buyers”).
AGREEMENT AND PLAN OF MERGERAgreement and Plan of Merger • April 18th, 2019 • Mateon Therapeutics Inc • Pharmaceutical preparations • Delaware
This Agreement and Plan of Merger (this “Agreement”) is made and entered into as of April 17, 2019, by and among Mateon Therapeutics, Inc., a Delaware corporation (the “Parent”), Oncotelic Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Parent (the “Merger Sub”), and Oncotelic, Inc., a Delaware corporation (the “Company”) with respect to the following facts:
